Open an account

Biontech SE

BNTX · NASDAQ

$91.17+$1.96 (+2.20%)TodayMarket closed ·
Prev close $89.21

About BNTX

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Employees
7,807
Headquarters
Mainz, Rheinland-Pfalz
Listed
Oct 10, 2019
Sector
Health Care
Industry
Biotechnology
Website
biontech.com

BNTX key statistics

Market cap
22.41B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.05M
Volume
1.84M
Open price
$89.50
High today
$91.44
Low today
$88.57
52 Week high
$124.00
52 Week low
$79.52

Biontech SE (BNTX) at a glance

As of Oct 20, 2026, Biontech SE (BNTX) shares are priced at $91.17, giving the company a market cap of 22.41B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $88.57 and $91.44. The current price is 2.9% above the day's low and 0.3% below its high.

Volume so far is 1.84M shares, above the average of 1.05M shares a day.

Over the past year Biontech SE has ranged from $79.52 to $124.00, and now sits 26% of the way up that range.

Biontech SE met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$3.24 per share against an estimate of -$2.13.

The average analyst price target is $126.58, 38.8% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

71%of 14 analyst ratings say Buy
  • Buy71.4%
  • Hold28.6%
  • Sell0.0%
Price target · 24 analystsAvg $126.58
Low
$85.85
Now
$91.17
High
$190.05

BNTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 78.1% on average.

  1. Q3 FY24: reported $0.81 per share against an estimate of -$1.59
  2. Q4 FY24: reported $1.08 per share against an estimate of $0.3319
  3. Q1 FY25: reported -$1.73 per share against an estimate of -$2.13
  4. Q2 FY25: reported -$1.60 per share against an estimate of -$2.05
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.2159
  6. Q4 FY25: reported -$1.25 per share against an estimate of -$0.1896
  7. Q1 FY26: reported -$2.10 per share against an estimate of -$2.27
  8. Q2 FY26: reported -$3.24 per share against an estimate of -$2.13

BNTX news

  • Press releasePRNewswire

    BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)

  • Vandana Singh

    Why Is BioNTech Stock Falling Tuesday?

  • Avi Kapoor

    Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

  • Neeraj Jain

    A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

  • Vandana Singh

    Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

  • Press releaseGlobe Newswire

    A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

  • Vandana Singh

    Why Is BioNTech Stock Gaining Monday?

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

Similar companies

Companies in the same industry as Biontech SE

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.